Format

Send to

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Haematol. 2013 Mar;26(1):43-56. doi: 10.1016/j.beha.2013.04.005. Epub 2013 May 25.

Treatment strategies for peripheral T-cell lymphomas.

Author information

1
Yale University School of Medicine, New Haven, CT, USA. francine.foss@yale.edu

Abstract

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically aggressive diseases historically associated with inferior outcomes using conventional lymphoma therapies. Aggressive first line therapy and consolidation with autologous stem cell transplantation has led to improved survival, but the majority of patients either fails to respond to therapy or are not transplant candidates. Novel approaches have included new classes of drug and biological agents, including antifolates, immunoconjugates, histone deacetylase (HDAC) inhibitors, monoclonal antibodies, and signal transduction inhibitors. Molecular profiling has led to identification of relevant pathways for future novel approaches.

PMID:
23768640
DOI:
10.1016/j.beha.2013.04.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center